Education
About Us
Working with TipRanks
Follow Us
Teladoc (TDOC)
NYSE:TDOC
TDOC Analyst Ratings
Moderate Buy
6 Buy
15 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TDOC Stock 12 Month Forecast
Average Price Target
$10.91
▲(44.89% Upside)
| Highest Price Target$14.00 | Average Price Target$10.91 | Lowest Price Target$8.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Argus Research
Reiterated
03/26/25
Bank of America Securities
Reiterated
03/17/25
J.P. Morgan
Reiterated
03/16/25
Truist Financial
Reiterated
03/11/25
TD Cowen
Reiterated
03/10/25
Canaccord Genuity
Reiterated
03/06/25
Wells Fargo
Reiterated
03/04/25
Goldman Sachs
Reiterated
03/03/25
Needham
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
William Blair
―
Hold
―
Reiterated
02/27/25
Teladoc (TDOC) Gets a Hold from William BlairWe view the quarter as relatively uneventful, with the company’s path to sustainable growth still unclear. As a result, we maintain our Market Perform rating. Our take Teladoc remains in a transitional phase, navigating lower growth with an emphasis on profitability. With a new CEO in place, we anticipate a sharper operating focus, particularly within BetterHelp, which could stabilize the stock and unlock value through strategic actions such as restructuring, asset sales, or innovative growth initiatives.
Leerink Partners
$10.5→$10
Hold
32.80%
Upside
Reiterated
02/27/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Merus (NASDAQ: MRUS) and Agilent (NYSE: A)
Robert W. Baird
$8→$9
Hold
19.52%
Upside
Reiterated
02/27/25
Teladoc price target raised to $9 from $8 at BairdTeladoc price target raised to $9 from $8 at Baird
Piper Sandler
$13→$12
Buy
59.36%
Upside
Reiterated
02/27/25
Teladoc price target lowered to $12 from $13 at Piper SandlerTeladoc price target lowered to $12 from $13 at Piper Sandler
Evercore ISI
$10
Hold
32.80%
Upside
Reiterated
02/27/25
Teladoc (TDOC) Receives a Hold from Evercore ISI
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Argus Research
Reiterated
03/26/25
Bank of America Securities
Reiterated
03/17/25
J.P. Morgan
Reiterated
03/16/25
Truist Financial
Reiterated
03/11/25
TD Cowen
Reiterated
03/10/25
Canaccord Genuity
Reiterated
03/06/25
Wells Fargo
Reiterated
03/04/25
Goldman Sachs
Reiterated
03/03/25
Needham
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
William Blair
―
Hold
―
Reiterated
02/27/25
Teladoc (TDOC) Gets a Hold from William BlairWe view the quarter as relatively uneventful, with the company’s path to sustainable growth still unclear. As a result, we maintain our Market Perform rating. Our take Teladoc remains in a transitional phase, navigating lower growth with an emphasis on profitability. With a new CEO in place, we anticipate a sharper operating focus, particularly within BetterHelp, which could stabilize the stock and unlock value through strategic actions such as restructuring, asset sales, or innovative growth initiatives.
Leerink Partners
$10.5→$10
Hold
32.80%
Upside
Reiterated
02/27/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teladoc (NYSE: TDOC), Merus (NASDAQ: MRUS) and Agilent (NYSE: A)
Robert W. Baird
$8→$9
Hold
19.52%
Upside
Reiterated
02/27/25
Teladoc price target raised to $9 from $8 at BairdTeladoc price target raised to $9 from $8 at Baird
Piper Sandler
$13→$12
Buy
59.36%
Upside
Reiterated
02/27/25
Teladoc price target lowered to $12 from $13 at Piper SandlerTeladoc price target lowered to $12 from $13 at Piper Sandler
Evercore ISI
$10
Hold
32.80%
Upside
Reiterated
02/27/25
Teladoc (TDOC) Receives a Hold from Evercore ISI
TDOC Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
3
3
1
0
0
Buy
6
7
5
11
12
Hold
22
18
13
25
30
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
28
19
36
42
Each month's total comprises the sum of three months' worth of ratings.
TDOC Financial Forecast
TDOC Stock Forecast FAQ
What is TDOC’s average 12-month price target, according to analysts?
Based on analyst ratings, Teladoc’s 12-month average price target is $10.91.
What is TDOC’s upside potential, based on the analysts’ average price target?
Teladoc has 44.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TDOC a Buy, Sell or Hold?
Teladoc has a consensus rating of Moderate Buy which is based on 6 buy ratings, 15 hold ratings and 0 sell ratings.
What is Teladoc’s price target?
The average price target for Teladoc is $10.91. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $8.00. The average price target represents 44.89% Increase from the current price of $7.53.
The highest analyst price target is $14.00 ,the lowest forecast is $8.00. The average price target represents 44.89% Increase from the current price of $7.53.
What do analysts say about Teladoc?
Teladoc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of TDOC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.